SCHEMBL4572271

SCHEMBL4572271

COC(=O)c1sccc1NS(=O)(=O)c1cccc(C(=O)O)c1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.62
LMNA P02545 1/20 0.62
HPGD P15428 1/20 0.62
ACLY P53396 4/20 0.55
KDM4E B2RXH2 1/20 0.54
PTK2B Q14289 1/20 0.54
KCNH2 Q12809 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.53
KMT2A Q03164 2/20 0.53
ALDH1A1 P00352 1/20 0.53
SLC10A6 Q3KNW5 1/20 0.52
MAPT P10636 1/20 0.51
SLC40A1 Q9NP59 1/20 0.49
PKM P14618 1/20 0.49
CASP3 P42574 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL532885 0.86 LMNA (0.78) TSHRLMNAHPGDACLYKCNH2
SCHEMBL2749317 0.86 LMNA (0.62) TSHRLMNAHPGDACLYKCNH2
SCHEMBL1198764 0.84 KCNH2 (0.67) TSHRLMNAHPGDACLYKDM4E
SCHEMBL2747338 0.84 LMNA (0.64) TSHRLMNAHPGDACLYKCNH2
SCHEMBL1200684 0.81 PARP14 (0.62) TSHRLMNAHPGDACLYKDM4E
SCHEMBL27999984 0.81 ACLY (0.57) TSHRLMNAHPGDACLYKDM4E
SCHEMBL2748496 0.81 HPGD (0.59) TSHRLMNAHPGDACLYKDM4E
SCHEMBL2750722 0.81 HPGD (0.59) TSHRLMNAHPGDACLYKDM4E
SCHEMBL1200203 0.81 LMNA (0.62) TSHRLMNAHPGDKCNH2ALDH1A1
SCHEMBL2748864 0.80 LMNA (0.71) TSHRLMNAHPGDKCNH2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120269864-A1 Arginine Derivatives with NP-I Antagonistic Activity GB06/019611.7 THERAPIES LIMITED (GB) 2012-10-25 US disclosed
US-8227606-B2 Arginine derivatives with NP-1 antagonistic activity ARK THERAPEUTICS, LTD. (GB) 2012-07-24 US disclosed
US-20120122862-A1 ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY GB06/019611.7 THERAPIES LIMITED (GB) 2012-05-17 US disclosed
US-8158789-B2 Arginine derivatives with NP-I antagonistic activity Ark Therapeutics Group Ltd. (GB) 2012-04-17 US disclosed
US-20100022525-A1 Arginine Derivatives with NP-I Antagonistic Activity GB06/019611.7 THERAPIES LIMITED (GB) 2010-01-28 US disclosed
WO-2008040979-A1 ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY ARK THERAPEUTICS LTD. (GB) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120269864-A1 Arginine Derivatives with NP-I Antagonistic Activity NPFFR1, NPR1, ARG1 TSHR 801/4885LMNA 4551/4885HPGD 529/4885
US-20120122862-A1 ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY NPFFR1, NPR1, ARG1 TSHR 801/4885LMNA 4551/4885HPGD 529/4885
US-20100022525-A1 Arginine Derivatives with NP-I Antagonistic Activity NPFFR1, NPR1, ARG1 TSHR 801/4885LMNA 4551/4885HPGD 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.